We are pleased to share with you the "TOP 10" research priorities in breast cancer based on feedback from more than a 1000 patients, families, caregivers and health care providers. Thank you to all those who participated and contributed to the process. A special note of appreciation to our steering committee members for their time and commitment to this initiative.

Here are the TOP 10 research priorities:

1. What biomarkers or intrinsic features of the tumour can be used to identify response to specific treatments and dosing schedules?
2. What is the role of immunotherapy for metastatic breast cancer?
3. How can treatment resistance be delayed, and minimized?
4. What causes (i.e. cellular, genomic changes) breast cancer cells to metastasize, and what changes allow them to penetrate the blood-brain barrier?
5. What is the right sequence of therapy in metastatic breast cancer?
6. Does local therapy (radiation or surgery to sites of metastatic disease) improve survival outcomes in metastatic breast cancer?
7. Is continuous treatment with systemic therapy (including HER2-targeted therapy and chemotherapy) better than intermittent treatment?
8. Does early palliative care improve outcomes for metastatic breast cancer patients?
9. What are the best methods of education for patients around treatment options and decision making that can lead to improved patient outcomes?
10. Can safer, more accurate methods, including blood tests of detecting spread of disease (including following curative intent treatment) be developed?

We are committed to:

1. Find funding opportunities to answer these questions, and put our research in action
2. To publish the full list of our top 27 questions that were ranked by you going into the final meeting, and make sure everyone's voice is heard.

ABOUT THE STUDY

BREAST CANCER IS THE MOST COMMON CANCER IN canadian WOMEN and women WORLDWIDE. ADVANCES IN TREATMENT ARE BEING MADE, SUCH THAT MORE WOMEN ARE LIVING LONGER WITH STAGE IV DISEASE.  TRADITIONALLY, CLINICAL TRIALS AND RESEARCH STUDIES ARE BASED ON QUESTIONS DETERMINED BY PHARMACEUTICAL COMPANIES AND RESEARCHERS WHO MAY, OR MAY NOT HAVE DIRECT INPUT FROM PATIENTS AND CAREGIVERS MOST AFFECTED BY THE DISEASE.

WE WANT TO CHANGE THAT.

WE INVITE PHYSICIANS, PATIENTS, and CAREGIVERS TO PARTICIPATE IN a SURVEY.

À PROPOS DE L’ÉTUDE

LE CANCER DU SEIN EST LE CANCER DU SEIN LE PLUS FRÉQUENT CHEZ LES FEMMES CANADIENNES ET CHEZ LES FEMMES À TRAVERS LE MONDE.  DES AVANCÉESDANS LE TRAITEMENT SONT FAITES,  CE QUI FAIT QUE PLUS DE FEMMES VIVENT PLUS LONGTEMPS AVEC UNE MALADIE DE STADE IV.  TRADITIONNELLEMENT, LES ÉTUDESCLINIQUES ET LA RECHERCHE SONT BASÉES SUR DES QUESTIONS DÉTERMINÉES PAR LES COMPAGNIES PHARMACEUTIQUES ET LES CHERCHEURS QUI PEUVENT, OU NON, AVOIR LA CONTRIBUTION DIRECTE DE PATIENTS ET DES INTERVENANTSLES PLUS TOUCHÉS PAR LA MALADIE.

Nous aimerions changer ça.

nous invitons les médecins, patients et aidants à participer à ce sondage.